Meta description: Spiro Medical raises $67 million in Series A funding to accelerate development of its asthma-focused neuromodulation system, supported by leading global investors.
Spiro Medical has closed a $67 million Series A funding round aimed at advancing its novel Pulmonary Neuromodulation System for asthma treatment. The capital will accelerate clinical development activities, positioning the company for regulatory engagement in the United States. Startup founders, medtech investors, and healthcare strategists may find this deal noteworthy given the unique blend of neuro-respiratory technology and implantable devices being targeted.
Who invested in this round?
The Series A was led by Andera Partners, with participation from Omega Funds and Sherpa Healthcare Partners. Additional backers include HSG, Supernova Invest, Northern Light Venture Capital, and Hero Inc., part of the Hero Enterprise group from India. The strong investor mix includes firms with deep expertise in medtech and global market expansion.
This syndicate brings financial resources and diverse strategic networks that may enable faster scale-up and international reach.
What does the funding mean for growth?
The $67 million allocation will be directed toward expanding clinical research, refining device design, and preparing for U.S. regulatory submissions. The focus is on integrating neuro-respiratory medicine with implantable technology and digital tools for respiratory conditions including asthma, COPD, and chronic cough.
By securing Series A funding within a year of its debut, Spiro Medical demonstrates early traction and validation of its approach. This pace reduces time-to-market risk and can strengthen competitive positioning against established respiratory device makers.
The funding also supports talent acquisition and infrastructure build-out, which are critical to advancing from pilot study data to broader clinical trials.
What are the board changes?
Alongside the capital infusion, Spiro Medical appointed Raphaël Wisniewski of Andera Partners, Claudio Nessi of Omega Funds, and Ouyang Xiangyu of Sherpa Healthcare Partners to its board of directors. Board members from lead investors often play direct roles in governance, strategic oversight, and investor relations, helping align future fundraising and commercialization plans.
Why these board additions matter
Such appointments can signal investor commitment beyond capital. They bring operational experience in scaling medical device ventures and navigating the complex landscape of regulatory approvals and reimbursement frameworks.
FAQ
1. How much did Spiro Medical raise in Series A funding?
$67 million.
2. Who led the investment round?
Andera Partners.
3. What will the funds be used for?
Clinical development, device refinement, and advancing toward U.S. regulatory approval.
4. Which conditions does the company aim to target?
Asthma, chronic obstructive pulmonary disease, and chronic cough.
5. Were there any changes to the board of directors?
Yes, three investor representatives from Andera, Omega, and Sherpa joined the board.
Conclusion
Spiro Medical’s Series A financing signals strong investor belief in its neuromodulation approach to respiratory care. The funds and governance changes position the company for accelerated clinical progress and regulatory engagement. For investors and founders, the deal underscores continued appetite for innovative medtech solutions, especially those addressing large unmet medical needs.
Disclaimer
This content is for informational purposes only and does not constitute financial advice. Readers should conduct their own due diligence.